Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8650528 | 0.82 | KMT2A (0.46) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL1477384 | 0.81 | KMT2A (0.41) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL15174366 | 0.79 | KMT2A (0.44) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL23108665 | 0.78 | KMT2A (0.42) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL21564194 | 0.78 | KMT2A (0.42) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL643674 | 0.78 | KMT2A (0.42) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL10379099 | 0.77 | — | — | |
| SCHEMBL23254089 | 0.76 | KMT2A (0.41) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL24245270 | 0.76 | KMT2A (0.41) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL20988251 | 0.76 | KMT2A (0.41) | KMT2AMEN1LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | ARBOR PHARMACEUTICALS, LLC | 2021-07-29 | — | — | US | claimed |
| US-9302977-B2 | Method of making monomethyl fumarate | XENOPORT, INC. (US) | 2016-04-05 | — | — | US | claimed |
| EP-2887934-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XenoPort, Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| EP-2854795-A1 | TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE | XenoPort, Inc. (US) | 2015-04-08 | — | — | EP | claimed |
| WO-2014197860-A1 | METHOD OF MAKING MONOMETHYL FUMARATE | XENOPORT, INC. (US) | 2014-12-11 | — | — | WO | claimed |
| US-20140364604-A1 | METHOD OF MAKING MONOMETHYL FUMARATE | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2014-12-11 | — | — | US | claimed |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-11-27 | — | — | US | claimed |
| WO-2014031844-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20140057917-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| WO-2013181451-A1 | TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE | XENOPORT, INC. (US) | 2013-12-05 | — | — | WO | claimed |
| US-20130324539-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | WILSHIRE PHARMACEUTICALS, INC. | 2013-12-05 | — | — | US | claimed |
| CN-1203837-C | Dye composition containing cationic direct dye and pyraole (1,5-alpha) pyradine as oxidative developing alkali and method of dyeing | OREAL (FR) | 2005-06-01 | — | — | CN | claimed |
| CN-1252988-A | Dye composition containing cationic direct dye and pyraole (1,5-alpha) pyradine as oxidative developing alkali and method of dyeing | OREAL (FR) | 2000-05-17 | — | — | CN | claimed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20210179573-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | ARBOR PHARMACEUTICALS, LLC | 2021-06-17 | — | — | US | disclosed |
| US-20190256480-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | ARBOR PHARMACEUTICALS, LLC | 2019-08-22 | — | — | US | disclosed |
| US-5808065-A | AMIDATION OF THE CORRESPONDING AMINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 1998-09-15 | — | — | US | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
| US-4686166-A | HIGH IMAGE DENSITY, ANTIFOGGING AGENT | HITACHI CHEMICAL CO. (JP) | 1987-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256480-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | MGMT, FH, SI | KMT2A 376/4885MEN1 1323/4885LMNA 4823/4885 |
| US-20140057917-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | KMT2A 578/4885MEN1 1212/4885LMNA 2857/4885 |
| US-20210179573-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | MGMT, FH, SI | KMT2A 376/4885MEN1 1323/4885LMNA 4823/4885 |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | KMT2A 578/4885MEN1 1212/4885LMNA 2857/4885 |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | KMT2A 438/4885MEN1 1620/4885LMNA 4660/4885 |
| US-20140364604-A1 | METHOD OF MAKING MONOMETHYL FUMARATE | FH, HNMT, FPGS | KMT2A 433/4885MEN1 1689/4885LMNA 4040/4885 |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | KMT2A 578/4885MEN1 1212/4885LMNA 2857/4885 |
| US-20130324539-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | MGMT, FH, SI | KMT2A 376/4885MEN1 1323/4885LMNA 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.